Grey matter volume loss in Parkinson’s Disease Psychosis and its relationship with serotonergic gene expression: A meta-analysis

Sara Pisani; Brandon Gunasekera; Yining Lu; Miriam Vignando; Dominic Ffytche; Dag Aarsland; K Ray Chaudhuri; Clive Ballard; Jee-Young Lee; Yu Kyeong Kim; Latha Velayudhan; Sagnik Bhattacharyya

doi:10.1016/j.neubiorev.2023.105081

Grey matter volume loss in Parkinson’s Disease Psychosis and its relationship with serotonergic gene expression: A meta-analysis

Sara Pisani, Brandon Gunasekera, Yining Lu, Miriam Vignando, Dominic Ffytche, Dag Aarsland, K Ray Chaudhuri, Clive Ballard, Jee-Young Lee, Yu Kyeong Kim, Latha Velayudhan, Sagnik Bhattacharyya

University of Exeter Medical School

Research output: Contribution to journal › Review article › peer-review

6 Citations (Scopus)

Abstract

Background: Neuroanatomical alterations underlying psychosis in Parkinson's Disease (PDP) remain unclear. We carried out a meta-analysis of MRI studies investigating the neural correlates of PDP and examined its relation with dopaminergic and serotonergic receptor gene expression. Methods: PubMed, Web of Science and Embase were searched for MRI studies (k studies = 10) of PDP compared to PD patients without psychosis (PDnP). Seed-based d Mapping with Permutation of Subject Images and multiple linear regression analyses was used to examine the relationship between pooled estimates of grey matter volume (GMV) loss in PDP and D1/D2 and 5-HT1a/5-HT2a receptor gene expression estimates from Allen Human Brain Atlas. Results: We observed lower grey matter volume in parietal-temporo-occipital regions (PDP n = 211, PDnP, n = 298). GMV loss in PDP was associated with local expression of 5-HT1a (b = 0.109, p = 0.012) and 5-HT2a receptors (b= −0.106, p = 0.002) but not dopaminergic receptors. Conclusion: Widespread GMV loss in the parieto-temporo-occipital regions may underlie PDP. Association between grey matter volume and local expression of serotonergic receptor genes may suggest a role for serotonergic receptors in PDP.

Original language	English
Article number	105081
Journal	Neuroscience and Biobehavioral Reviews
Volume	147
DOIs	https://doi.org/10.1016/j.neubiorev.2023.105081
Publication status	Published - Apr 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.neubiorev.2023.105081

Cite this

Pisani, S., Gunasekera, B., Lu, Y., Vignando, M., Ffytche, D., Aarsland, D., Chaudhuri, K. R., Ballard, C., Lee, J.-Y., Kim, Y. K., Velayudhan, L., & Bhattacharyya, S. (2023). Grey matter volume loss in Parkinson’s Disease Psychosis and its relationship with serotonergic gene expression: A meta-analysis. Neuroscience and Biobehavioral Reviews, 147, Article 105081. https://doi.org/10.1016/j.neubiorev.2023.105081

@article{374f42b291644df5ba92cb407549a899,

title = "Grey matter volume loss in Parkinson{\textquoteright}s Disease Psychosis and its relationship with serotonergic gene expression: A meta-analysis",

abstract = "Background: Neuroanatomical alterations underlying psychosis in Parkinson's Disease (PDP) remain unclear. We carried out a meta-analysis of MRI studies investigating the neural correlates of PDP and examined its relation with dopaminergic and serotonergic receptor gene expression. Methods: PubMed, Web of Science and Embase were searched for MRI studies (k studies = 10) of PDP compared to PD patients without psychosis (PDnP). Seed-based d Mapping with Permutation of Subject Images and multiple linear regression analyses was used to examine the relationship between pooled estimates of grey matter volume (GMV) loss in PDP and D1/D2 and 5-HT1a/5-HT2a receptor gene expression estimates from Allen Human Brain Atlas. Results: We observed lower grey matter volume in parietal-temporo-occipital regions (PDP n = 211, PDnP, n = 298). GMV loss in PDP was associated with local expression of 5-HT1a (b = 0.109, p = 0.012) and 5-HT2a receptors (b= −0.106, p = 0.002) but not dopaminergic receptors. Conclusion: Widespread GMV loss in the parieto-temporo-occipital regions may underlie PDP. Association between grey matter volume and local expression of serotonergic receptor genes may suggest a role for serotonergic receptors in PDP.",

author = "Sara Pisani and Brandon Gunasekera and Yining Lu and Miriam Vignando and Dominic Ffytche and Dag Aarsland and Chaudhuri, {K Ray} and Clive Ballard and Jee-Young Lee and Kim, {Yu Kyeong} and Latha Velayudhan and Sagnik Bhattacharyya",

note = "Funding Information: SB, LV, DA, DF, KRC and CB are in receipt of funding from Parkinson{\textquoteright}s UK for a clinical trial in Parkinson{\textquoteright}s disease psychosis. SP PhD studentship is funded by Parkinson{\textquoteright}s UK. The funding source had no involvement in this research. SB is supported by grants from the National Institute of Health Research (NIHR) Efficacy and Mechanism Evaluation scheme and Parkinson{\textquoteright}s UK. SB has participated in advisory boards for or received honoraria as a speaker from Reckitt Benckiser, EmpowerPharm/SanteCannabis and Britannia Pharmaceuticals. All of these honoraria were received as contributions toward research support through King's College London , and not personally. SB also has collaborated with Beckley Canopy Therapeutics/Canopy Growth (investigator-initiated research) wherein they supplied study drug for free for charity (Parkinson's UK) and NIHR (BRC) funded research. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. LV has collaborated with Beckley Canopy Therapeutics/ Canopy Growth (investigator-initiated research) wherein they supplied study drug for free for charity (Parkinson's UK) and NIHR (BRC) funded research. Funding Information: SB, LV, DA, DF, KRC and CB are in receipt of funding from Parkinson's UK for a clinical trial in Parkinson's disease psychosis. SP PhD studentship is funded by Parkinson's UK. The funding source had no involvement in this research. SB is supported by grants from the National Institute of Health Research (NIHR) Efficacy and Mechanism Evaluation scheme and Parkinson's UK. SB has participated in advisory boards for or received honoraria as a speaker from Reckitt Benckiser, EmpowerPharm/SanteCannabis and Britannia Pharmaceuticals. All of these honoraria were received as contributions toward research support through King's College London, and not personally. SB also has collaborated with Beckley Canopy Therapeutics/Canopy Growth (investigator-initiated research) wherein they supplied study drug for free for charity (Parkinson's UK) and NIHR (BRC) funded research. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. LV has collaborated with Beckley Canopy Therapeutics/ Canopy Growth (investigator-initiated research) wherein they supplied study drug for free for charity (Parkinson's UK) and NIHR (BRC) funded research. Publisher Copyright: {\textcopyright} 2023 The Authors",

year = "2023",

month = apr,

doi = "10.1016/j.neubiorev.2023.105081",

language = "English",

volume = "147",

journal = "Neuroscience and Biobehavioral Reviews",

issn = "0149-7634",

}

Pisani, S , Gunasekera, B, Lu, Y, Vignando, M , Ffytche, D , Aarsland, D , Chaudhuri, KR, Ballard, C, Lee, J-Y, Kim, YK, Velayudhan, L & Bhattacharyya, S 2023, 'Grey matter volume loss in Parkinson’s Disease Psychosis and its relationship with serotonergic gene expression: A meta-analysis', Neuroscience and Biobehavioral Reviews, vol. 147, 105081. https://doi.org/10.1016/j.neubiorev.2023.105081

TY - JOUR

T1 - Grey matter volume loss in Parkinson’s Disease Psychosis and its relationship with serotonergic gene expression: A meta-analysis

AU - Pisani, Sara

AU - Gunasekera, Brandon

AU - Lu, Yining

AU - Vignando, Miriam

AU - Ffytche, Dominic

AU - Aarsland, Dag

AU - Chaudhuri, K Ray

AU - Ballard, Clive

AU - Lee, Jee-Young

AU - Kim, Yu Kyeong

AU - Velayudhan, Latha

AU - Bhattacharyya, Sagnik

N1 - Funding Information: SB, LV, DA, DF, KRC and CB are in receipt of funding from Parkinson’s UK for a clinical trial in Parkinson’s disease psychosis. SP PhD studentship is funded by Parkinson’s UK. The funding source had no involvement in this research. SB is supported by grants from the National Institute of Health Research (NIHR) Efficacy and Mechanism Evaluation scheme and Parkinson’s UK. SB has participated in advisory boards for or received honoraria as a speaker from Reckitt Benckiser, EmpowerPharm/SanteCannabis and Britannia Pharmaceuticals. All of these honoraria were received as contributions toward research support through King's College London , and not personally. SB also has collaborated with Beckley Canopy Therapeutics/Canopy Growth (investigator-initiated research) wherein they supplied study drug for free for charity (Parkinson's UK) and NIHR (BRC) funded research. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. LV has collaborated with Beckley Canopy Therapeutics/ Canopy Growth (investigator-initiated research) wherein they supplied study drug for free for charity (Parkinson's UK) and NIHR (BRC) funded research. Funding Information: SB, LV, DA, DF, KRC and CB are in receipt of funding from Parkinson's UK for a clinical trial in Parkinson's disease psychosis. SP PhD studentship is funded by Parkinson's UK. The funding source had no involvement in this research. SB is supported by grants from the National Institute of Health Research (NIHR) Efficacy and Mechanism Evaluation scheme and Parkinson's UK. SB has participated in advisory boards for or received honoraria as a speaker from Reckitt Benckiser, EmpowerPharm/SanteCannabis and Britannia Pharmaceuticals. All of these honoraria were received as contributions toward research support through King's College London, and not personally. SB also has collaborated with Beckley Canopy Therapeutics/Canopy Growth (investigator-initiated research) wherein they supplied study drug for free for charity (Parkinson's UK) and NIHR (BRC) funded research. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. LV has collaborated with Beckley Canopy Therapeutics/ Canopy Growth (investigator-initiated research) wherein they supplied study drug for free for charity (Parkinson's UK) and NIHR (BRC) funded research. Publisher Copyright: © 2023 The Authors

PY - 2023/4

Y1 - 2023/4

N2 - Background: Neuroanatomical alterations underlying psychosis in Parkinson's Disease (PDP) remain unclear. We carried out a meta-analysis of MRI studies investigating the neural correlates of PDP and examined its relation with dopaminergic and serotonergic receptor gene expression. Methods: PubMed, Web of Science and Embase were searched for MRI studies (k studies = 10) of PDP compared to PD patients without psychosis (PDnP). Seed-based d Mapping with Permutation of Subject Images and multiple linear regression analyses was used to examine the relationship between pooled estimates of grey matter volume (GMV) loss in PDP and D1/D2 and 5-HT1a/5-HT2a receptor gene expression estimates from Allen Human Brain Atlas. Results: We observed lower grey matter volume in parietal-temporo-occipital regions (PDP n = 211, PDnP, n = 298). GMV loss in PDP was associated with local expression of 5-HT1a (b = 0.109, p = 0.012) and 5-HT2a receptors (b= −0.106, p = 0.002) but not dopaminergic receptors. Conclusion: Widespread GMV loss in the parieto-temporo-occipital regions may underlie PDP. Association between grey matter volume and local expression of serotonergic receptor genes may suggest a role for serotonergic receptors in PDP.

AB - Background: Neuroanatomical alterations underlying psychosis in Parkinson's Disease (PDP) remain unclear. We carried out a meta-analysis of MRI studies investigating the neural correlates of PDP and examined its relation with dopaminergic and serotonergic receptor gene expression. Methods: PubMed, Web of Science and Embase were searched for MRI studies (k studies = 10) of PDP compared to PD patients without psychosis (PDnP). Seed-based d Mapping with Permutation of Subject Images and multiple linear regression analyses was used to examine the relationship between pooled estimates of grey matter volume (GMV) loss in PDP and D1/D2 and 5-HT1a/5-HT2a receptor gene expression estimates from Allen Human Brain Atlas. Results: We observed lower grey matter volume in parietal-temporo-occipital regions (PDP n = 211, PDnP, n = 298). GMV loss in PDP was associated with local expression of 5-HT1a (b = 0.109, p = 0.012) and 5-HT2a receptors (b= −0.106, p = 0.002) but not dopaminergic receptors. Conclusion: Widespread GMV loss in the parieto-temporo-occipital regions may underlie PDP. Association between grey matter volume and local expression of serotonergic receptor genes may suggest a role for serotonergic receptors in PDP.

UR - http://www.scopus.com/inward/record.url?scp=85148365790&partnerID=8YFLogxK

U2 - 10.1016/j.neubiorev.2023.105081

DO - 10.1016/j.neubiorev.2023.105081

M3 - Review article

SN - 0149-7634

VL - 147

JO - Neuroscience and Biobehavioral Reviews

JF - Neuroscience and Biobehavioral Reviews

M1 - 105081

ER -

Grey matter volume loss in Parkinson’s Disease Psychosis and its relationship with serotonergic gene expression: A meta-analysis

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this